Introduction: A small number of retrospective studies suggest AIHA to be associated with an increased risk to suffer from thromboembolic events. However, based on these studies it remains unclear whether the complement activation per is a risk factor to develop thromboembolic events in AIHA patients. The aim of this retrospective study is to investigate the incidence of thromboembolic events and the relation to complement activation in a cohort of AIHA patients. Patients and Methods: We included 77 patients in this study with a positive DAT and hemolytic parameters or with AIHA diagnosis based on the medical report. The included patients were screened for thromboembolic events (TEE) and have been stratified in groups with and without comple...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Objective: Increased soluble levels of complement effectors have been demonstrated in active anti-ne...
Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolut...
INTRODUCTION A small number of retrospective studies suggest AIHA to be associated with an increa...
International audienceThrombotic manifestations are a hallmark of many auto-immune diseases (AID), s...
Thrombotic manifestations are a hallmark of many auto-immune diseases (AID), specially of warm autoi...
Autoimmune hemolytic anemia (AIHA) is increasingly recognized as a strong risk factor for venous thr...
BACKGROUND AND OBJECTIVES: Atypical hemolytic uremic syndrome is a form of thrombotic microangiopath...
Introduction: Autoimmune hemolytic anemia (AIHA) is an acquired autoimmune disorder caused by develo...
International audienceObjectives: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaem...
BACKGROUND: Intravenous immunoglobulin (IVIg) treatment is a well-known treatment that has been used...
Patients with autoimmune disorders are at an increased risk of venous thromboembolism (VTE), but thi...
OBJECTIVE: To determine the incidence of arterial thrombotic events (ATE) and venous thromboembolism...
Objective: Increased soluble levels of complement effectors have been demonstrated in active anti-ne...
OBJECTIVE: To determine the incidence of arterial thrombotic events (ATE) and venous thromboembolism...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Objective: Increased soluble levels of complement effectors have been demonstrated in active anti-ne...
Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolut...
INTRODUCTION A small number of retrospective studies suggest AIHA to be associated with an increa...
International audienceThrombotic manifestations are a hallmark of many auto-immune diseases (AID), s...
Thrombotic manifestations are a hallmark of many auto-immune diseases (AID), specially of warm autoi...
Autoimmune hemolytic anemia (AIHA) is increasingly recognized as a strong risk factor for venous thr...
BACKGROUND AND OBJECTIVES: Atypical hemolytic uremic syndrome is a form of thrombotic microangiopath...
Introduction: Autoimmune hemolytic anemia (AIHA) is an acquired autoimmune disorder caused by develo...
International audienceObjectives: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaem...
BACKGROUND: Intravenous immunoglobulin (IVIg) treatment is a well-known treatment that has been used...
Patients with autoimmune disorders are at an increased risk of venous thromboembolism (VTE), but thi...
OBJECTIVE: To determine the incidence of arterial thrombotic events (ATE) and venous thromboembolism...
Objective: Increased soluble levels of complement effectors have been demonstrated in active anti-ne...
OBJECTIVE: To determine the incidence of arterial thrombotic events (ATE) and venous thromboembolism...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Objective: Increased soluble levels of complement effectors have been demonstrated in active anti-ne...
Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolut...